X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs NATCO PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS NATCO PHARMA NOVARTIS/
NATCO PHARMA
 
P/E (TTM) x 300.9 19.6 1,535.6% View Chart
P/BV x 25.6 18.8 136.6% View Chart
Dividend Yield % 1.4 0.6 233.3%  

Financials

 NOVARTIS   NATCO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-17
NATCO PHARMA
Mar-14
NOVARTIS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs855877 97.5%   
Low Rs666424 157.2%   
Sales per share (Unadj.) Rs219.0223.4 98.0%  
Earnings per share (Unadj.) Rs19.131.1 61.5%  
Cash flow per share (Unadj.) Rs20.340.3 50.4%  
Dividends per share (Unadj.) Rs10.005.00 200.0%  
Dividend yield (eoy) %1.30.8 171.1%  
Book value per share (Unadj.) Rs307.0219.5 139.8%  
Shares outstanding (eoy) m29.9633.07 90.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.52.9 119.3%   
Avg P/E ratio x39.820.9 190.2%  
P/CF ratio (eoy) x37.516.1 232.0%  
Price / Book Value ratio x2.53.0 83.6%  
Dividend payout %52.416.1 325.3%   
Avg Mkt Cap Rs m22,77921,504 105.9%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,3931,128 123.5%   
Avg. sales/employee Rs Th9,736.2NM-  
Avg. wages/employee Rs Th2,066.8NM-  
Avg. net profit/employee Rs Th849.0NM-  
INCOME DATA
Net Sales Rs m6,5627,389 88.8%  
Other income Rs m702167 419.8%   
Total revenues Rs m7,2647,556 96.1%   
Gross profit Rs m2591,793 14.4%  
Depreciation Rs m36304 11.8%   
Interest Rs m7366 2.0%   
Profit before tax Rs m9171,290 71.1%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m345309 111.8%   
Profit after tax Rs m5721,027 55.7%  
Gross profit margin %3.924.3 16.3%  
Effective tax rate %37.623.9 157.2%   
Net profit margin %8.713.9 62.7%  
BALANCE SHEET DATA
Current assets Rs m9,7313,681 264.3%   
Current liabilities Rs m1,8303,123 58.6%   
Net working cap to sales %120.47.6 1,592.7%  
Current ratio x5.31.2 451.0%  
Inventory Days Days4989 54.4%  
Debtors Days Days2559 42.9%  
Net fixed assets Rs m577,685 0.7%   
Share capital Rs m141331 42.5%   
"Free" reserves Rs m9,0566,670 135.8%   
Net worth Rs m9,1967,259 126.7%   
Long term debt Rs m0955 0.0%   
Total assets Rs m11,49911,957 96.2%  
Interest coverage x128.44.5 2,839.4%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 92.3%   
Return on assets %5.011.7 43.2%  
Return on equity %6.214.2 44.0%  
Return on capital %10.120.7 48.5%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m1293,445 3.7%   
Fx outflow Rs m1,734703 246.7%   
Net fx Rs m-1,6052,743 -58.5%   
CASH FLOW
From Operations Rs m-3801,440 -26.3%  
From Investments Rs m4,208-1,089 -386.3%  
From Financial Activity Rs m-3,318-353 940.7%  
Net Cashflow Rs m510-1 -34,234.9%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 2.0 7.8 25.5%  
FIIs % 1.6 16.6 9.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.0 82.7%  
Shareholders   41,647 25,395 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

OPEC Meeting; Upcoming IPOs; IDBI Bank, Emami among Top Stocks in Action Today(Pre-Open)

Indian share markets edged up on Friday with Nifty 50 closing above 10,800-levels, even as broader global markets remained weak.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 25, 2018 09:29 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STERLING BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS